Dr. Kiran  Pai  Md image

Dr. Kiran Pai Md

21298 Olean Blvd
Port Charlotte FL 33949
941 291-1181
Medical School: Other - 2000
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: No
License #: ME91256
NPI: 1023036860
Taxonomy Codes:

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy


Dr. Kiran Pai is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:00790 Description:Anesth surg upper abdomen Average Price:$1,602.50 Average Price Allowed
By Medicare:
HCPCS Code:00520 Description:Anesth chest procedure Average Price:$775.45 Average Price Allowed
By Medicare:
HCPCS Code:00740 Description:Anesth upper gi visualize Average Price:$695.58 Average Price Allowed
By Medicare:
HCPCS Code:00810 Description:Anesth low intestine scope Average Price:$668.57 Average Price Allowed
By Medicare:
HCPCS Code:01810 Description:Anesth lower arm surgery Average Price:$470.91 Average Price Allowed
By Medicare:
HCPCS Code:01996 Description:Hosp manage cont drug admin Average Price:$300.00 Average Price Allowed
By Medicare:
HCPCS Code:36556 Description:Insert non-tunnel cv cath Average Price:$250.00 Average Price Allowed
By Medicare:

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found


Doctor Name
Diagnostic Radiology
Infectious Disease
Pulmonary Disease
Internal Medicine
Internal Medicine
Infectious Disease
Pulmonary Disease
*These referrals represent the top 10 that Dr. Pai has made to other doctors


Diperoxovanadate can substitute for H(2)O(2) at much lower concentration in inducing features of premature cellular senescence in mouse fibroblasts (NIH3T3). - Mechanisms of ageing and development
Stress induced premature senescence (SIPS) in mammalian cells is an accelerated ageing response and experimentally obtained on treatment of cells with high concentrations of H(2)O(2), albeit at sub-lethal doses, because H(2)O(2) gets depleted by abundant cellular catalase. In the present study diperoxovanadate (DPV) was used as it is known to be stable at physiological pH, to be catalase-resistant and to substitute for H(2)O(2) in its activities at concentrations order of magnitudes lower. On treating NIH3T3 cells with DPV, SIPS-like morphology was observed along with an immediate response of rounding of the cells by disruption of actin cytoskeleton and transient G2/M arrest. DPV could bring about growth arrest and senescence associated features at 25 μM dose, which were not seen with similar doses of either H(2)O(2) or vanadate. A minimal dose of 150 μM of H(2)O(2) was required to induce similar affects as 25 μM DPV. Increase in senescent associated markers such as p21, HMGA2 and PAI-1 was more prominent in DPV treated cells compared to similar dose of H(2)O(2). DPV-treated cells showed marked relocalization of Cyclin D1 from nucleus to cytoplasm. These results indicate that DPV, stable inorganic peroxide, is more efficient in inducing SIPS at lower concentrations compared to H(2)O(2).Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C. - Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN-α (peg-IFN-α) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN-α once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of D-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P < .05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P > .05) No significant difference in plasma D-dimer levels was observed during peg-IFN-α treatment (P > .05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P < .05). Our results indicated that treatment with peg-IFN-α may be associated with enhanced fibrinolysis.

Map & Directions

21298 Olean Blvd Port Charlotte, FL 33949
View Directions In Google Maps

Nearby Doctors

21298 Olean Blvd
Port Charlotte, FL 33949
941 291-1181
21298 Olean Blvd
Port Charlotte, FL 33949
941 291-1181
21298 Olean Blvd
Port Charlotte, FL 33949
941 291-1181